Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia

European Psychiatry

Volumn 21, Issue 1, 2006, Pages 11-20

  Martin, José Luis R ^a,b   Pérez, Víctor ^c   Sacristán, Montse ^a   Rodríguez Artalejo, Fernando ^d   Martínez, Cristóbal ^e   Álvarez, Enric ^c  

^a Castile La Mancha Health Research Foundation FISCAM   (Spain)

^b UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e H Alarcos   (Spain)

Author keywords

Clinical trials; Meta analysis; Schizophrenia; Systematic review

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; HUMAN; LONG TERM CARE; META ANALYSIS; PATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 32644445530     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2005.09.009     Document Type: Short Survey

References (53)

1. G.L. Daumit, R.M. Crum, E. Guallar, N.R. Powe, A.B. Primm, and D.M. Steinwachs Outpatients prescriptions for atypical antipsychotics for African Americans, Hispanics, and Whites in the United States Arch. Gen. Psychiatry 60 2003 121 128
2. J.A. Lieberman Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis J. Clin. Psychiat. 57 11 1996 68 71
3. Z.A. Sarif Common treatment goals of antipsychotics: acute treatment J. Clin. Psychiat. 59 19 1998 5 8
4. S.R. Kay, and A. Fiszbein The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr. Bull. 13 1987 261 275
5. G. Chouinard, B. Jones, G. Remington, D. Blooom, D. Addington, and G.W. MacEwan A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients J. Clin. Psychopharm. 13 1993 25 40
6. S.H. Hamilton, D.A. Revicki, L.A. Genduso, and C.M. Beasley Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American Double-blind trial Neuropsychopharmacol 18 1998 41 49
7. S.E. Purdon, B. Jones, E. Stip, A. Labelle, D. Addington, and S.R. David Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Canadian Collaborative Group for Research on cognition in schizophrenia Arch. Gen. Psychiatry 57 2000 249 258
8. A. Khan, S.R. Khan, G. Walens, R. Kolts, and E.L. Giller Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports Neuropsychopharmacol 28 2003 552 557
9. M. Hotopf, R. Churchill, and G. Lewis Pragmatic randomised controlled trials in psychiatry Br. J. Psychiat. 175 1999 217 223
10. E.J. Frackiewicz, J.J. Sramek, J.M. Herrera, N.M. Kurtz, and N.R. Cutler Ethnicity and antipsychotic response Ann. Pharmacother. 31 1997 1360 1369
11. T. Colton Statistics in medicine 1974 Little, Brown and Company Boston
12. J.J. Deeks, and D.G. Altman Effect measures for meta-analysis of trials with binary outcomes M. Egger G. Davey Smith D.G. Altman Systematic reviews in health care: meta-analysis in context (2001 BMJ Publication Group London
13. J.P.T. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analysis BMJ 327 2003 557 560
14. R.W. Buchanan, A. Breier, B. Kirkpatrick, P. Ball, and W.T. Carpenter Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome Am. J. Psychiat. 155 1998 751 760
15. J.M. Kane, S.R. Marder, N.R. Schooler, W.C. Wirshing, D. Umbricht, and R.W. Baker Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison Arch. Gen. Psychiatry 58 2001 965 972
16. R. Rosenheck, J. Cramer, W. Xu, J. Thomas, W. Henderson, and L. Frisman A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia N. Engl. J. Med. 337 1997 809 815
17. E. Guirguis, G. Voineskos, J. Gray, and E. Schierman Clozapine (Leponex) vs. Chlorpromaxine (Largactil) in acute schizophrenia (a double-blind controlled study) Curr. Ther. Res. 21 1977 707 719
18. J. Kane, G. Honigfeld, J. Singer, and H. Meltzer Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine Arch. Gen. Psychiatry 45 1988 789 796
19. C.A. León Therapeutic effect of clozapine. A 4-year follow up of a controlled clinical trial Acta Psychiatr. Scand. 59 1979 471 480
20. L.A. Arvanitis, and B.G. Miller Seroquel Trial 13 Study Group. Multiple fixed doses of 'Seroquel' (Quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo Biol. Psychiat. 42 1997 233 246
21. D.L. Copolov, C.G.G. Link, and B. Kowalcyk A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636 'Seroquel') and haloperidol in schizophrenia Psychol. Med. 30 2000 95 105
22. R.A. Emsley, J. Raniwalla, P.J. Bailey, and A.M. Jones A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenia patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment Int. Clin. Psychopharm. 15 2000 121 131
23. J. Peuskens, and C.G.G. Link A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia Acta Psychiatr. Scand. 96 1997 265 273
24. C.M. Beasley, G. Tollefson, P. Tran, W. Satterlee, T. Sanger, and S. Hamilton Olanzapine versus placebo and haloperidol. Acute phase results of the North American double-blind olanzapine trial Neuropsychopharmacol 14 1996 11 123
25. C.M. Beasley Jr., S.H. Hamilton, A.M. Crawford, Ma. Dellva, G.D. Tollefson, and P.V. Tran Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial Eur. Neuropsychopharm. 7 1997 125 137
26. S.H. Hamilton, E.T. Edgell, D.A. Revicki, and A. Breier Functional outcome in schizophrenia: a comparison of olanzapine and haloperidol in a European sample Int. Clin. Psychopharm. 15 2000 245 255
27. J.A. Lieberman, G. Tollefson, M. Tohen, A.I. Green, R.E. Gur, and R. Kahn Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol Am. J. Psychiat. 160 2003 1396 1404
28. G.D. Tollefson, C.M. Beasley Jr., P.V. Tran, Js. Street, J.A. Krueger, and R.N. Tamura Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial Am. J. Psychiat. 154 1997 457 465
29. R.R. Conley, C.A. Tamminga, J.J. Bartko, C. Richardson, M. Peszke, and J. Lingle Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia Am. J. Psychiat. 155 1998 914 920
30. E. Ceskova, and J. Svestka Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses Pharmacopsychiatry 26 1993 121 124
31. A. Claus, J. Bollen, H. De Cuyper, M. Eneman, M. Malfroid, and J. Peuskens Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study Acta Psychiatr. Scand. 85 1992 295 305
32. J.G. Csernansky, R. Mahmoud, and R. Brenner A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia N. Engl. J. Med. 346 2002 16 22
33. R.A. Emsley Risperidone Working Group. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study Schizophr. Bull. 25 1999 721 729
34. A.H. Heck, P.M. Haffmans, I.W. Groot, and E. Hoencamp Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial Schizophr. Res. 46 2000 97 105
35. S.R. Marder, and R.C. Meibach Risperidone in the treatment of schizophrenia Am. J. Psychiat. 151 1994 825 835
36. J. Peuskens Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol Brit. J. Psychiat. 166 1995 712 726
37. D.A. Wirshing, B.D. Marshall Jr., M.F. Green, J. Mintz, S.R. Marder, and W.C. Wirshing Risperidone in treatment-refractory schizophrenia Am. J. Psychiat. 156 1999 1374 1379
38. J. Volavka, P. Czobor, B. Sheitman, J.P. Lindenmayer, L. Citrome, and J.P. McEvoy Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder Am. J. Psychiat. 159 2002 255 262
39. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (4th ed) (DSM-IV) 1994 DC: APA Washington
40. D. Moher, K.F. Schulz, and D.G. Altman The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials Lancet 357 2001 1191 1194
41. Review Manager (RevMan) [Computer program]. Version 4.2 for Windows. Oxford, England: The Cochrane Collaboration, 2003.
42. Borenstein M, Rothstein H. Comprehensive Meta-AnalysisTM. Biostat® 1999. www.MetaAnalysis.com.
43. S. Leucht, T.R. Barnes, W. Kissling, R.R. Engel, C. Correll, and J.M. Kane Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials Am. J. Psychiat. 160 2003 1209 1222
44. S. Leucht, K. Wahlbeck, J. Hamann, and W. Kissling New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis Lancet 361 2003 1581 1589
45. S.M. Gilbory, A.M. Bagnall, L. Duggan, and A. Tuunainen Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review) The Cochrane library, issue 1 2004 John Wiley & Sons, Ltd Chichester, UK
46. L. Duggan, M. Fenton, R.M. Dardennes, A. El-Dosoky, and S. Indran Olanzapine for schizophrenia (Cochrane Review) The Cochrane library, issue 1 2004 John Wiley & Sons, Ltd Chichester, UK
47. M. Srisurapanont, C. Disayavanish, and K. Taimkaew Quetiapine for schizophrenia (Cochrane Review) The Cochrane library, issue 1 2004 John Wiley & Sons, Ltd Chichester, UK
48. Lieberman J, McEvoy J, Stroup S. Clinical antipsychotic trials in intervention effectiveness (CATIE). Comparative effectiveness of antipsychotic medications in patients with schizophrenia. http://www.catie.unc.edu/ schizophrenia/synopsis.html.
49. J.M. Davis, N. Chen, and I.D. Glick A meta-analysis of the efficacy of second-generation antipsychotics Arch. Gen. Psychiatry 60 2003 553 564
50. J. Geddes, N. Freemantle, P. Harrison, and P. Bebbington Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis BMJ 321 2000 1371 1376
51. J.L.R. Martin, V. Ṕrez, M. Sacristán, and E. Alvarez Is grey literature essential for a better control of publication bias in psychiatry? An example from three meta-analysis of schizophrenia Eur. Psychiatry 2005 (In press)
52. C. Rummel, J. Hamann, Kissling, and S. Leucht New generation antipsychotics for first episode schizophrenia (Cochrane Review) The Cochrane library, issue 1 2004 John Wiley & Sons, Ltd Chichester, UK
53. S. Gilbody, K. Wahlbeck, and C. Adams Randomized controlled trials in schizophrenia: a critical perspective on the literature Acta Psychiatr. Scand. 105 2002 243 251